Lennox-Gastaut Syndrome Treatment in Turkey

What is Lennox-Gastaut Syndrome?

Lennox-Gastaut Syndrome is a developmental and epileptic encephalopathy that usually begins during early childhood. It is characterised by multiple seizure types, particularly tonic, atonic, and atypical absence seizures, along with characteristic EEG findings such as slow spike-and-wave discharges and generalised paroxysmal fast activity. Many patients also experience developmental, cognitive, behavioural, or learning difficulties.

What is the Importance of Timely Treatment?

Timely treatment helps identify the cause of the patient's condition, classify the seizure type, reduce seizure frequency, prevent injury, and support cognitive function and daily skills. Specialist diagnosis should be especially timely in patients with severe, frequent seizure disorders that cannot be managed easily, are associated with falls, or are accompanied by developmental irregularities.

What are the Common Symptoms of Lennox-Gastaut Syndrome?

• Tonic Seizures: Sudden stiffening of the muscles, which may occur particularly during sleep.
• Atonic Seizures: Sudden loss of muscle tone that can cause head drops or falls.
• Atypical Absence Seizures: Episodes of reduced awareness that may begin and end gradually.
• Myoclonic Seizures: Brief, sudden muscle jerks that may affect one or more parts of the body.
• Developmental or Learning Difficulties: Cognitive and developmental challenges may occur or become more evident over time.
• Behavioural Changes: Attention, communication, mood, or behavioural difficulties may accompany the condition.

Causes and Risk Factors of Lennox-Gastaut Syndrome

Causes

• Brain Developmental Abnormalities: Structural brain abnormalities can contribute to LGS.
• Genetic Conditions: Genetic variants and chromosomal abnormalities may be associated with LGS.
• Brain Injury: Hypoxic-ischemic injury, birth-related brain injury, or previous neurological damage may contribute.
• Central Nervous System Infections: Conditions such as encephalitis or meningitis may cause brain injury associated with LGS.
• Tuberous Sclerosis Complex: Certain neurocutaneous disorders can be associated with LGS.
• Metabolic Disorders: Some metabolic or mitochondrial disorders may contribute to epileptic encephalopathy.
• Unknown Cause: In some patients, no specific underlying cause can be identified despite detailed evaluation.

Risk Factors

• Early-Onset Epilepsy: Severe epilepsy beginning in infancy or early childhood may increase the risk.
• Infantile Spasms: A history of infantile spasms is associated with subsequent development of LGS in some children.
• Structural Brain Abnormalities: Developmental or acquired brain lesions can increase susceptibility.
• Genetic Disorders: Certain genetic conditions may predispose children to severe epilepsy.
• Previous Brain Injury: Significant neurological injury can contribute to epileptic encephalopathy.
• CNS Infections: Previous serious infections affecting the brain may increase risk.
• Neurocutaneous Disorders: Conditions such as tuberous sclerosis can be associated with LGS.

Latest Research and Technologies in the Treatment of Lennox-Gastaut Syndrome in Turkey

• Recent advances in LGS care include improved long-term video-EEG monitoring, high-resolution epilepsy-protocol MRI, genetic testing, advanced seizure evaluation, ketogenic dietary therapy, and neuromodulation techniques such as vagus nerve stimulation (VNS) and epilepsy surgery assessment for selected drug-resistant patients. Future advances in adaptive and personalised stimulation may transform LGS management. Turkish clinical studies have also looked at treatments such as intravenous immunoglobulin (IVIG) as an additional option for some patients with difficult-to-control seizures.